Neuroblastoma and its Target Therapies: A Medicinal Chemistry Review
Open Access
- 26 March 2024
- journal article
- review article
- Published by Wiley in ChemMedChem
- Vol. 19 (9) , e202300535
Abstract
Neuroblastoma (NB) is a childhood malignant tumour belonging to a group of embryonic tumours originating from progenitor cells of the sympathoadrenal lineage. The heterogeneity of NB is reflected in the survival rates of those with low and intermediate risk diseases who have survival rates ranging from 85 to 90 %. However, for those identified with high‐risk Stage 4 NB, the treatment options are much more limited. For this group, current treatment consists of immunotherapy (monoclonal antibodies) in combination with anti‐cancer drugs and has a 40 to 50 % survival rate. The purpose of this review is to summarise NB research from a medicinal chemistry perspective and to highlight advances in targeted drug therapy in the field. The review examines the medicinal chemistry of a number of drugs tested in research, some of which are currently under clinical trial. It concludes by proposing that future medicinal chemistry research into NB should consider other possible target therapies and adopt a multi‐target drug approach rather than a one‐drug‐one‐target approach for improved efficacy and less drug‐drug interaction for the treatment of NB Stage 4 (NBS4) patients.Keywords
This publication has 101 references indexed in Scilit:
- Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with NeuroblastomaTargeted Oncology, 2022
- The quest to develop an effective therapy for neuroblastomaJournal of Cellular Physiology, 2021
- Molecular targeting therapies for neuroblastoma: Progress and challengesMedicinal Research Reviews, 2020
- Neuroblastoma pathogenesis: deregulation of embryonic neural crest developmentCell and tissue research, 2017
- FRED and HYBRID docking performance on standardized datasetsJournal of Computer-Aided Molecular Design, 2012
- Small‐Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer TherapeuticsChemMedChem, 2010
- Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)Pediatric Blood & Cancer, 2010
- Hedgehog signalling in colon cancer and stem cellsEMBO Molecular Medicine, 2009
- Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancerBreast Cancer Research and Treatment, 2007
- In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)International Journal of Cancer, 2002